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NeuroprotectionParkinson's disease (PD) is a common chronic neurodegenerative disorder, usually of idiopathic origin.
Symptoms including tremor, bradykinesia, rigidity and postural instability are caused by the progressive loss of
dopaminergic neurons in the nigrostriatal region of the brain. Symptomatic therapies are available but no treat-
ment slows or prevents the loss of neurons. Neuroinﬂammation has been implicated in its pathogenesis. To this
end, the present study utilises the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin to
reproduce the pattern of cell death evident in PD patients. Herein, the role of a potential regulator of an immune
response, the endocannabinoid system (ECS), is investigated. The most prevalent endocannabinoid,
2-arachidonoylglycerol (2-AG) (3 and 5mg/kg), was added exogenously and its enzymatic degradation inhibited
to provide protection against MPTP-induced cell death. Furthermore, the addition of DFU (25mg/kg), a selective
inhibitor of inﬂammatory mediator cyclooxygenase-2 (COX-2), potentiated these effects. Levels of 2-AG were
shown to be upregulated in a time- and region-speciﬁc manner following MPTP administration, indicating that
the ECS represents a natural defencemechanism against inﬂammation, potentiation ofwhich could provide ther-
apeutic beneﬁts. The results expand the current understanding of the role that this signalling system has and its
potential inﬂuence in PD.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Parkinson's disease (PD) is the second most common neurode-
generative disease in the world after Alzheimer's disease, with
0.3% of the population affected in industrialised countries; its preva-
lence increasing with age (de Lau and Breteler, 2006). It is
characterised by motor abnormalities including tremor, muscle ri-
gidity, paucity of voluntary movements and postural instability.se of support; CB, cannabinoid;
2, cyclo-oxygenase-2; DOPAC,
stem; FAAH, fatty acid amide
raphy; IL, interleukin; MAGL,
inium; MPTP, 1-methyl-4-phe-
PPAR, peroxisome proliferator-
cta; TH, tyrosine hydroxylase;
.
. This is an open access article underThe main neuropathological feature is the loss of dopaminergic neu-
rons in the substantia nigra pars compacta (SNpc) and their projec-
tions to the striata (Dauer and Przedborski, 2004), although the
exact cause of this degeneration is not certain in the majority of
cases. Certain processes have been implicated in the generation of
the disease, however. Substantial evidence supports the view that in-
ﬂammation plays a pivotal role in the death of neurons in the basal gan-
glia. Activated forms of the resident immune cells of the central nervous
system, microglia, have been found in the brains of PD patients at post-
mortem (McGeer et al., 1988), while elevated levels of pro-
inﬂammatory cytokines such as tumor necrosis factor-alpha (TNF-α),
interleukin (IL)-1β and IL6 have been measured in the cerebrospinal
ﬂuid of patients (Mogi et al., 1994a, 1994b; Blum-Degen et al., 1995;
Muller et al., 1998).
The endocannabinoid system (ECS) is a signalling pathway com-
posed of at least two G-protein coupled receptors (cannabinoid
(CB)1 and CB2) and their endogenous ligands, involved in functions
ranging from movement control to analgesia and emotional-
affecting roles. The ECS has been targeted in models of variousthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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tion: Alzheimer's disease (Ramirez et al., 2005; van der Stelt et al.,
2006), Huntington's disease (Lastres-Becker et al., 2003; Sagredo
et al., 2007; Dowie et al., 2010; Blazquez et al., 2011) and amyotro-
phic lateral sclerosis (Bilsland et al., 2006) have all been targeted
with neuroprotective results. Exogenous addition of the most ubiq-
uitous of the natural cannabinoid ligands, 2-arachidonoylglycerol
(2-AG), has been shown to limit expression of pro-inﬂammatoryme-
diator cyclooxygenase-2 (COX-2) (Zhang and Chen, 2008), possibly
through activation of CB1 receptors, thereby protecting neurons. 2-
AG has previously proven to be neuroprotective (Panikashvili et al.,
2005) and is concentrated in the areas affected by PD (Bisogno
et al., 1999), making it an attractive therapeutic target.
The two major endocannabinoids have their signalling tightly con-
trolled by enzymatic activity. Each has a distinct pathwaywith different
enzymes involved: N-arachidonoylethanolamine (anandamide) is pri-
marily metabolised by fatty acid amide hydrolase (FAAH), while 2-AG
is principally degraded by monoacylglycerol lipase (MAGL) (Dinh
et al., 2002). A study of serine hydrolases in the mouse brain ascribed
around 85% of 2-AG metabolism to this enzyme (Blankman et al.,
2007). This study utilises the N-aryl carbamate URB602 and the more
recently synthesised JZL184, as these have been found to be both potent
and selective inhibitors of MAGL (King et al., 2007; Long et al., 2009b,
2010; Pan et al., 2009) and therefore suitable for use in manipulation
of the ECS. In addition, a selective COX-2 inhibitor, DFU, was used to de-
terminewhether the effects of exogenous 2-AG administration could be
amended or potentiated, while also providing mechanistic information
about the endocannabinoid. Herein we investigated if increasing levels
of 2-AG via its exogenous addition or inhibition of its metabolic enzyme
would lead to neuroprotection in the 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine hydrochloride (MPTP) mouse model.Fig. 1. Effect of two doses of 2-AG on nigral MPTP neurotoxicity. (A) Representative photomicro
either saline orMPTP (scale bar is 200 μm). (B) Both doses of 2-AG similarly attenuatedMPTP-in
striatal dopaminergic ﬁbres (C) or striatal dopamine content (D). Data aremean± SEM, n— nu
pared to equivalent saline-treated group; # p b 0.05, compared to vehicle and MPTP group (Ne2. Methods
2.1. Animals and treatment
Twelve week-old male C57BL6/J mice (Charles River Laboratories,
UK; 4–12 per time point) received intraperitoneal (i.p.) injections of
MPTP (SigmaAldrich, Poole, UK) at 30 mg/kg freebase dissolved in
0.9% saline solution — one injection per day for ﬁve consecutive days,
before being sacriﬁced by decapitation at 21 days after the last injection.
Control mice received saline only. This treatment was in accordance
with published guidelines (Jackson-Lewis and Przedborski, 2007). All
procedures were in accordance with the Animals Scientiﬁc Procedures
Act (1986) and approved by the Home Ofﬁce (Dundee, UK). Mice
were housed in appropriately sized cages with access to food and
water ad libitum, with a 12-hour light–dark cycle (lights on at 7 am). Ex-
perimentswere carried out in accordancewith the EuropeanCommuni-
ties Council Directive (63/2010/EU) with local ethical approval, a
project license under the UK Scientiﬁc Procedures Act (1986),2.2. Drug treatments
2-AG (3 or 5 mg/kg), CP55,940 (0.5 mg/kg) (both Tocris Bioscience,
Ellisville, MO), URB602 (10 mg/kg), JZL184 (40 mg/kg) (both Cayman
Chemicals, Ann Arbor, MI) and DFU (25 mg/kg) (Merck, Damstadt,
Germany) were dissolved via gentle soniﬁcation in a vehicle consisting
of ethanol, chremophor EL (SigmaAldrich) and saline solution at a ratio
of 1:1:18 v/v/v. All drugs were administered by i.p. injection 1×/day for
3 days prior toMPTP treatment, throughout the treatment and until sac-
riﬁce. Controlmice received vehicle only. The amount of compoundwas
chosen based on previous studies (2-AG: Panikashvili et al., 2001;graphs of TH-stained SN sections following treatment with 3 mg/kg or 5 mg/kg 2-AGwith
duced loss of TH-positive neurons but the protective effect did not translate to protection of
mbers displayed on bars. One-way ANOVA: F(5, 23)= 3.998, p=0.0093. * p b 0.05, com-
wman–Keuls post hoc test).
Table 1
Effect of drugs used on striatalMPP+ levels. No differences were seen in striatal levels ofMPP+ betweenmice receiving drugs or those receiving saline. Data aremean± SEM, n=4–8 per
group (one-way ANOVA followed by Newman–Keuls post hoc test; n.s.).
Saline 2-AG URB602 JZL184 DFU
MPP+ (μg/g wet tissue) 12.31 ± 2.90 9.62 ± 0.33 12.89 ± 0.38 13.39 ± 2.51 10.13 ± 0.88
38 R.B. Mounsey et al. / Experimental Neurology 273 (2015) 36–44CP55,940: Fontanellas et al., 2005; URB602: Comelli et al., 2007; JZL184:
Nomura et al., 2011; and DFU: Riendeau et al., 1997).2.3. Immunostaining and stereological counting
Brains were extracted and post-ﬁxed in 4% paraformaldehyde (PFA)
for 24 h before being cryoprotected in 30% sucrose in 0.1 M phosphate
buffer. Brains were then snap frozen in 2-methylbutane and stored at
−80 °C until use. Sections of the SNpc and striatumwere cut at a thick-
ness of 30 μm on a Leica CM1900 cryostat (Leica Microsystems GmbH
Wetzlar, Germany) and placed in 24- or 48-well plates in 0.1M PBS con-
taining 0.1% sodium azide. Immunostaining was carried out using the
free-ﬂoating technique, as described previously (Sathe et al., 2012),
with primary antibody incubation taking place at 4 °C for 48 hwith rabbit
anti-tyrosine hydroxylase (TH; 1:1000;Millipore,Watford, UK) in 2%nor-
mal goat serum. Sections were washed in 0.1 M PBS, mounted on
gelatinised slides and counter-stained with Nissl reagent and cover-
slipped with Entellan (Merck). Counting of TH- and Nissl-positive cellsFig. 2. Effect of twoMAGL inhibitors, URB602 and JZL184, onMPTP toxicity in the SNpc. (A) Rep
or JZL184 with either saline or MPTP (scale bar is 200 μm). (B) Neither treatment signiﬁcantly
numbers displayed on bars. One-way ANOVA: F(5, 19)= 3.500, p=0.02. # p b 0.05, comparedwas performed using regular light microscopy (AxioImager M1, Carl
Zeiss, Hertfordshire, UK) and the optical fractionator method (West,
1993) (Stereo Investigator Version 7, BMF Bioscience, Magdeburg,
Germany).
2.4. High performance liquid chromatography analysis
High-performance liquid chromatography (HPLC) with electro-
chemical detection was used to measure striatal levels of dopamine
and 3,4-dihydroxyphenylacetic acid (DOPAC) (Sathe et al., 2012).
2.5. Striatal 1-methyl-4-phenylpyridinium iodide (MPP+) levels
Liquid chromatography with on-line ultraviolet detection/tan-
dem mass spectrometry (LC–UV–MS–MS) was used to measure
striatal levels of MPP+ following drug treatments. Brieﬂy, mice re-
ceived treatment as described above and, 90 min after a single
MPTP injection (30 mg/kg), mice were sacriﬁced. The striata wereresentative photomicrographs of TH-stained SN sections following treatment with URB602
attenuated MPTP-induced reductions in TH-positive neurons. Data are mean ± SEM, n —
to saline treated control groups and JZL184+MPTP group (Newman–Keuls post hoc test).
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then prepared as described above. Following centrifugation, 2 μl of
sample was injected onto a Hichrom 5 μm C18 column (Hichrom,
Theale, UK). The mobile phase consisted of 80% 0.1% formic acid
in water/20% 0.1% formic acid in acetonitrile. Flow rate was
0.2 ml/min. MPP+ was detected by a photodiode array detector
set to 295 nm, and a triple quadrupole mass spectrometre with a
mass to charge ratio of 170–128 at 32 V and 1.9 mTorr
(ThermoSurveyor PDA/TSQ Quantum, ThermoScientiﬁc, Loughbor-
ough, UK). Data were collected and processed using Xcalibur 2.0.7 SP1.2.6. Home cage observation
Locomotor activity was recorded using 32 Activity Cages (Ugo Basile,
Varese, Italy) placed in a quiet holding room. They consist of two rows of
horizontal infra-red beams (1 cm distance) and monitor horizontal
ambulations and vertical rearings as number of beam breaks.
Animals were placed into freshly saw-dusted Perspex home cages
(42 cm × 26.5 cm × 15 cm). Animals were placed into the novel cage
and allowed to freely explore the environment for 60 min. Beam breaks
due to horizontal and vertical movements were automatically recorded
and transmitted by an interface and online displayed using Activity soft-
ware (Ugo Basile). Locomotor activity was monitored continuously in 1
minute intervals and then pooled for a period of 60 min. In addition
the number of faecal balls was noted for the observation period as amea-
sure of anxiety.Fig. 3. Effect of dualMAGL and COX-2 inhibition onMPTP neurotoxicity. (A) Representative pho
either saline orMPTP (scale bar is 200 μm). (B)MPTP causes a reduction in TH-positive nigral ne
a co-treatment, the drugs result in a pronounced effect, providing recovery to saline TH levels. Da
the results pooled. One-way ANOVA: F(7, 52)= 5.129, p=0.0002. ## p b 0.01 compared to veh
man–Keuls post hoc test).2.7. Gait analysis (CatWalk)
Gait analysiswas conducted using the CatWalk system (CatWalk 7.1,
Noldus IT,Wageningen, Netherlands) in a dimly lit room. The apparatus
consists of an enclosed walkway (50 cm in length) consisting of LED-
illuminated glass and an under-ﬂoor camera for recording footfalls
and footprint patterns. Recordings were digitised and autoanalysed
using CatWalk 7.1 software (Noldus IT). The mice were placed at one
end of the walkway and left to cross to the other end freely. They
were removed only after they had made not less than three compliant
runs, i.e., subjects crossed the walkway in less than 5 s. Two infrared
beamswere used to detect the arrival of themouse at each end and con-
trolled (start/stop) data acquisition. Endpoints included relative paw
position (hind overlapping/non-overlapping with front paws), timing
(stand, swing and step cycle), base of support, pressure and dimensions
of each footfall,which enabled calculation of stride length, pawdistance,
and regularity index (preferred paw placement sequence during walk-
ing) and were averaged for all compliant runs. The apparatus was
cleaned with 70% ethanol between animals.
2.8. Statistical analysis
Data were analysed in GraphPad Prism 5 for Windows (GraphPad
Software, La Jolla, CA). All values are expressed as the mean± SEM. Nor-
mal distribution of the data was tested and the homogeneity of variance
conﬁrmed with the Kolmogorov–Smirnov test. For data sets, one-way
analysis of variance (ANOVA) was used to analyse differences amongtomicrographs of TH-stained SN sections following treatmentwith DFU and/or JZL184with
urons. This is attenuated by treatmentwithDFU or JZL184 alone and,when administered as
ta aremean±SEM, n— numbers displayed onbars. Experimentwas performed twice and
icle and saline group; * p b 0.05, *** p b 0.001, compared to vehicle andMPTP group (New-
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the data was normally distributed. When ANOVA showed signiﬁcant dif-
ferences post hoc testing was used tomake comparisons betweenmeans:
Dunnett's post hoc test was used for time-course studies and Student–
Newman–Keuls post hoc test was used to make pair-wise comparisons
in all other studies. The null hypothesiswas rejected at the 0.05 level. Out-
liers were eliminated based on descriptive statistics performed by SPSS
(IBM SPSS Statistics Version 21 for Windows, Hampshire, UK). To assess
sampling strategy and homogeneity of the group coefﬁcient of variance
(CV) and coefﬁcient of error (CE) (Gundersen and Jensen, 1987) were
assessed.3. Results
3.1. 2-AG attenuates MPTP-induced degeneration of nigrostriatal neurons
but not in a dose-dependent manner
TH, the enzyme responsible for the rate-limiting step in the syn-
thesis of dopamine, was stained. It was found that the speciﬁed
doses of 2-AG provided equal levels of neuroprotection when
assessing TH-positive neuron numbers in the SNpc through stereo-
logical counting (Fig. 1A and B). 2-AG alone did not affect neuronal
survival. The number of TH-positive cells was reduced by 35.8% fol-
lowing sub-acute MPTP administration compared to saline-treated
control brains. This reduction was attenuated by both 3 mg/kg and
5 mg/kg 2-AG. There were some changes found between groups
when Nissl, a non-speciﬁc neuronal marker, was used to stain cells,
with 3 mg/kg 2-AG and saline, and MPTP with vehicle, or 3 mg/kg
2-AG showing signiﬁcant deviations from control numbers
(Fig. 1B). Statistics on CV and CE can be found in Supplemental
Table 1.Fig. 4. Striatal density and HPLC analysis of dopamine and DOPAC levels following MPTP treatm
sections following drug treatments. (B) No attenuation of MPTP-induced decreases in striatal d
treated equivalents. Experiment was performed twice and the results pooled. One-way ANOV
lower than their saline-treated equivalents, but addition of DFU or JZL184 does not signiﬁcantly
are reduced after MPTP treatment. Other values are not signiﬁcantly altered. One-way ANOVA:
periments were performed twice and the results pooled. # p b 0.05, ## p b 0.01, #### p b 0.0The effect of 2-AGon striatal innervation bydopaminergicﬁbreswas
evaluated by measuring TH immunoreactivity, giving an indication of
the density of striatal ﬁbres. Both doses of 2-AG failed to signiﬁcantly at-
tenuate the MPTP-induced reduction in TH immunoreactivity although
an increase in mean density is evident.
Treatment with the CB1/CB2 receptor agonist CP55,940 and the
endocannabinoid 2-AG (5mg/kg) did not produce attenuation of striatal
dopamine loss induced by MPTP at levels considered to be signiﬁcant
(Fig. 1C; and MPTP + vehicle: 0.98 ± 0.33 ng/mg wet tissue weight;
MPTP + CP55,940: 2.06 ± 0.31 ng/mg wet tissue weight). The same
was the case for DOPAC (Fig. 1D; MPTP + vehicle: 0.59 ± 0.12 ng/mg
wet tissue weight; MPTP + CP55,940: 0.62 ± 0.09 ng/mg wet tissue
weight).
Since mice were receiving drugs as pre- and post-treatments, it was
important to ensure that these did not interfere with the metabolism of
MPTP into the active toxin MPP+. Liquid chromatography with ultra-
violet detection and tandem mass spectrometric detection was used to
measure the striatal content of the toxin following infusion of the drug
and MPTP to check that drugs did not interfere with the bio-activation
of the toxin (Table 1). Data show no change in striatal MPP+ levels
across the treatments.3.2. Signiﬁcant neuroprotection following inhibition of MAGL by JZL184
after MPTP-induced degeneration of nigrostriatal neurons but not URB602
MAGL inhibitors were utilised to increase 2-AG levels through inhi-
bition of its selective metabolic enzyme, and thereby provide another
means of increasing levels of the endocannabinoid besides exogenous
addition. URB602 administration did not lead to an attenuation of
MPTP-induced reduction in TH-positive cell numbers. On the other
hand JZL184 administration led to signiﬁcantly higher TH-positive cellent and administration of DFU and JZL184. (A) Representative scanned images of striatal
ensity is shown. DFU and co-treatment samples are signiﬁcantly lower than their saline-
A: F(7, 67) = 6.339, p= 0.0152. (C) Dopamine levels of all treatments are signiﬁcantly
attenuate this reduction. One-way ANOVA: F(7, 67)= 7.748, p b 0.0001. (D) DOPAC levels
F(7, 67)= 3.603, p=0.0024. Data are mean ± SEM, n— numbers displayed on bars. Ex-
001, compared to an equivalent saline-treated group (Newman–Keuls post hoc test).
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found in Supplemental Table 2.3.3. DFU augments the neuroprotection provided by JZL184
Since exogenous 2-AG has previously been found tomediate protec-
tion from excitotoxicity in hippocampal neurons through inhibition of
COX-2 expression (Zhang and Chen, 2008), it was considered that this
may be the mechanism of action by which dopaminergic neurons are
protected in theMPTPmodel. To test this theory, the selective COX-2 in-
hibitor DFU (25mg/kg)was administered tomice by i.p. injection. In ad-
dition, JZL184 (40 mg/kg) was added in combination with DFU to see if
the neuroprotective potential it shows alone can be potentiated by the
co-administration of this agent.
As expected,MPTP caused a highly signiﬁcant death-rate among TH-
positive neurons in the SNpc, with around 50% of these neurons lost
(Fig. 3A and B). This is attenuated by treatment with DFU or JZL184
alone. However, treatment with the two agents in combination pro-
duced additive beneﬁts, leading to total recovery of TH-positive neuronFig. 5. Activity and gait-related parameters were not affected byMPTP. Global activity during 60
(B). TreatmentwithMPTP, DFU or JZL184 does not affect themean stride length (C) and the pro
from either the front (E) or hind (F) paws. Data are mean ± SEM, n = 7–11 per group.numbers to saline levels. Statistics on CV and CE can be found in Supple-
mental Table 3.
Striatal dopaminergic innervation was again evaluated by measuring
the optical density of TH immunoreactivity. There was no signiﬁcant at-
tenuation of MPTP-induced decreases in striatal density when DFU or
JZL184was administered, although there is a trend towards this result fol-
lowing a similar pattern to nigral TH protection. But only immunoreactiv-
ity values ofMPTPonly andMPTP+DFU treated brainswere signiﬁcantly
lower than their equivalent saline-treated samples (Fig. 4A and B).
HPLC analysis was used to determine the levels of dopamine and
DOPAC in the striatum following treatments.MPTP induced a signiﬁcant
reduction in striatal dopamine levels (Fig. 4C), but none of the treat-
ments succeeded in attenuating this to a signiﬁcant level. This situation
is mirrored when striatal levels of DOPAC were measured (Fig. 4D)
3.4. The behaviour of the mice is not affected when assessed 26 days after
MPTP
Behavioural analysis was undertaken to assess whether treatments
would induce behavioural abnormalities in the mice. Tests were per-min home cage exploration yielded no difference in horizontal (A) or vertical movements
portion of normal step patterns (D). Similarly, therewas no effect on base of support (BOS)
42 R.B. Mounsey et al. / Experimental Neurology 273 (2015) 36–44formed 26 days after MPTP exposure to establish full-blown PD inmice.
Neither activity-related parameters (vertical and horizontalmovement)
nor gait-related proxies of the Catwalk (stride length, regularity index
or base of support) differed between cohorts (Fig. 5). Although there
was some variation between groups, the most consistent feature was
a small reduction in gait (base of support) for both front and hind
paws in the MPTP cohort (Fig. 5E,F). However, despite severe frank
cell loss in the substantia nigra, animals were not motorically impaired
when exposed to MPTP.
3.5. 2-AG is released in a region- and time-speciﬁc manner
To ﬁnd whether the endocannabinoid system represents a natural
defence mechanism against the speciﬁc deleterious effects that the
MPTP model induces in mice, levels of endogenous 2-AG were mea-
sured by LC–MS–MS at several time-points following a chronic treat-
ment regimen which mirrors that administered to the mice in the
previous treatment studies.
Following MPTP administration, levels of 2-AG in the ventral mid-
brain (Fig. 6A) are increased signiﬁcantly by 2 days after the end of
MPTP administration. A signiﬁcant upregulation of the endocannabinoid
is also evident 4 days after MPTP but levels return close to control after
7 days. The situation in the striatum is different (Fig. 6B). There is initially
no change in 2-AG levels following MPTP administration followed by a
decline which reaches levels signiﬁcantly lower than those seen in con-
trol tissues at 7 days after treatment. These low levels are maintained
until the end of the study at 21 days.
4. Discussion
Our data show that increasing levels of the endocannabinoid 2-AG,
either by its exogenous addition or inhibiting its metabolism by using
selective inhibitors of this enzymatic activity, is protective against the
neurodegenerative effects induced by the neurotoxin MPTP. This effect
can be augmented by the addition of the selective COX-2 inhibitor DFU.
Treatmentwith 2-AG inmice attenuated the loss of TH-positive neu-
rons but not striatal levels of dopamine caused by the chronic regimen
of MPTP. The level of protection may be higher with an increased
dose. Although the dose-dependent treatment shown here showed no
signiﬁcant changes in protection against MPTP toxicity between
3 mg/kg and 5 mg/kg, a higher dose may produce protection, as sug-
gested by the effect of higher 2-AG levels resulting from chronic treat-
ment with the selective MAGL inhibitor JZL184. Higher levels of 2-AG,
due toMAGL inhibition by JZL184 have also been implicated in synapticFig. 6. Time-course of 2-AG levels measured by mass spectrometry in the ventral midbrain an
midbrain increase following MPTP administration, showing a signiﬁcant increase between
23) = 9.881, p b 0.0001. (B) Striatal levels of 2-AG show no initial increase and decline steep
0.0001. Data are mean ± SEM, n— numbers per time-point displayed on bars. ** p b 0.01, *** p
lowing the end of MPTP treatment (30 mg/kg daily administration)).and cognitive improvements in a model of Alzheimer's disease (Zhang
et al., 2014).
The CB1/CB2 receptor agonist CP55,940 caused a small, but not signif-
icant increase in the levels of striatal dopamine following MPTP insult. It
seems likely that activation of CB1 is required for neuroprotection
(Chiarlone et al., 2014; Blazquez et al., 2015). The issue of whether acti-
vation of CB1 is protective or harmful to neurons is onewhich has provid-
ed much debate, with a number of different perspectives supporting the
notion that CB1 receptor activation is neuroprotective (Melis et al., 2006;
Iuvone et al., 2007; Chen et al., 2011), although other studies argue that
neuroprotection is CB1 receptor activation-independent or dependent
on its blockade (Nomura et al., 2011; Lastres-Becker et al., 2005; Kelsey
et al., 2009; Mukhopadhyay et al., 2010; Garcia et al., 2011). Another
study shows that activation of CB2 receptors is crucial to the neuroprotec-
tion provided by the non-selective agonist WIN55,212-2 (Price et al.,
2009). Expression of CB2 receptors, previously thought to only exist in
peripheral areas (reviewed by Atwood andMackie, 2010), is upregulated
at times of stress and immune reaction, particularly in microglia. Activa-
tion of CB2 receptors has been shown in models of Huntington's disease
to be effective against many of the same pathological changes which
occur in PD, including microglial activation and neuroinﬂammation
(Palazuelos et al., 2009). These pathways may be initiated by speciﬁc ac-
tivation of the two previously cloned receptors as well as those pharma-
cologically characterised, but not yet cloned (reviewed by Mackie and
Stella, 2006). An example of this activation of these “new players” is
that of the CB2 receptor and an abnormal-cannabidiol-sensitive receptor,
which has been shown to provide neuroprotection by preventing the ac-
cumulation of microglia (Kreutz et al., 2009). It has previously been sug-
gested that 2-AG protects neurons by inhibiting the expression of the
inﬂammatory enzyme COX-2 (Zhang and Chen, 2008). 2-AG is also a
substrate for COX-2 (Kozak et al., 2000), which metabolizes 2-AG into
potentially harmful prostaglandins: a process that may exacerbate any
inﬂammation and degeneration. 2-AG can also directly reduce the levels
of reactive oxygen species, cytokines and prostaglandin E2 (Zhang and
Chen, 2008). Therefore, limiting the expression of COX-2 would on the
one hand prevent the accumulation of possible inﬂammatory mediators
generated by COX-2-mediated 2-AG metabolism and on the other hand
more 2-AGwould be available for possible neuroprotective effects medi-
ated via cannabinoid receptors. Zhang and Chen (2008) also showed that
the inhibition of COX-2 expression was dependent on the CB1 receptor.
This evidence, along with that outlined above, indicates that the most
successful utilisation of the ECS in neuroprotection could result from
non-selective activation of the cannabinoid receptors, making 2-AG a
useful therapeutic agent to meet this aim since 2-AG can confer
neuroprotection through its anti-inﬂammatory and anti-oxidantd striatum of mice following sub-chronic MPTP treatment. (A) 2-AG levels in the ventral
2 and 4 days after treatment, before returning to control levels. One-way ANOVA: F(6,
ly between 7 and 21 days after MPTP treatment. One-way ANOVA: F(6, 22) = 16.80, p b
b 0.001, **** p b 0.0001, compared to saline group (Dunnett's post hoc test) (d— days fol-
43R.B. Mounsey et al. / Experimental Neurology 273 (2015) 36–44properties. To take full advantage of all the numerous neuroprotective
properties that 2-AG has shown, including anti-inﬂammatory and anti-
oxidant, a manipulation of more than one of the cannabinoid receptors
is required. 2-AG seems suitable as a treatment option, not only is it a po-
tent and abundant agonist of both cannabinoid receptors as it is a natural
ligand, and thus avoids the potential complicationswhich can occurwith
exogenously administered synthetic agonists. In addition to this, the per-
oxisome proliferator-activated receptor (PPAR)-γ has been shown to be
crucial in some of the neuroprotective effects produced by 2-AG (Du
et al., 2011). Thus, concurrent use of a PPARγ receptor agonist, such as
rosiglitazone, may potentiate the beneﬁts of 2-AG in the MPTP model.
An alternative to the exogenous addition of 2-AG is the inhibition of its
metabolic enzyme, MAGL. We utilised JZL184, a potent inhibitor of this
enzyme (Long et al., 2009a, 2009b) alongsideURB602, amore established
inhibitor (Hohmann et al., 2005). However, another group has cast doubt
on the potency of URB602 as a MAGL inhibitor and its preference over
FAAH in vitro (Vandevoorde et al., 2007). URB602 has been shown to be
less effective against MPTP toxicity in the present study, but whether
this is as a direct result of the drug being an inferior inhibitor of MAGL,
and therefore less effective at increasing 2-AG levels, is not clear. JZL184
in itself proved to be protective against MPTP-induced cell death. This is
in line with other reports, which show the neuroprotective effect of
JZL184 (Nomura et al., 2011; Fernandez-Suarez et al., 2014). In addition
to inhibition of MAGL and thus increasing levels of 2-AG, it seems likely
that JZL184 might itself act directly on the CB2 receptor, but not the CB1
receptor (Aymerich et al., 2015).
As pharmacological inhibition ofMAGL has proven effective in atten-
uatingMPTP-induced cell death, another way the effect of MAGL inhibi-
tion could be evaluated is the genetic ablation ofMAGL bymanipulation
ofMgII. However, this technique has been shown to reduce the expres-
sion and functional capacity of CB1 receptors (Schlosburg et al., 2010).
This questions the long-term use of JZL184 as a viable treatment option,
as the data from this study indicate that chronically elevated levels of 2-
AG antagonise the brain ECS via CB1 adaptations (Schlosburg et al.,
2010). Interestingly, a sustained pharmacological disruption of FAAH
had no such effect. However, it is clear that activation of the ECS is im-
portant and effective in neuroprotection, therefore such full, functional
incapacity should be avoided. Studies using other models have shown
that the pharmacological elevation of endocannabinoid levels is effec-
tive against toxic insults, includingβ-amyloid toxicitywhen administer-
ing an inhibitor of cannabinoid re-uptake at sub-chronic levels (van der
Stelt et al., 2006), so further work is merited in the MPTP model. An
adapted treatment regime could be considered to avoid the potential
problems outlined by Schlosburg et al. (2010) and discover whether
JZL184 remains effective in a shorter treatment regimen and/or at a
lower dose.
The combination of JZL184 with the speciﬁc COX-2 inhibitor DFU
had amore pronounced effect onMPTP-induced toxicity. Previous stud-
ies have already shown that inhibition of COX-2 has a neuroprotective
effect on MPTP-induced toxicity (Teismann et al., 2003). Interestingly,
by using malonate it is reported that JZL184 leads to an increase of 2-
AG levels, which in turn increases malonate-induced cell damage
(Valdeolivas et al., 2013). A JZL184-induced increase in 2-AG was not
shown to lead to neurotoxicity. But it might also be the case that in
the models used the beneﬁcial effects of JZL184 as well as 2-AG itself
on the CB2 receptor outweigh the deleterious effects mediated by the
2-AG increase. The beneﬁcial effects seen by the addition of the COX-2
inhibitor DFU, besides acting directly on COX-2 itself, might have been
due to an attenuation of the pro-inﬂammatory prostaglandin E2-G.
We found that the protection on dopaminergic neurons in the SNpc
due to DFU and/or JZL184 did not extend to the striatal ﬁbres. But this is
in accordance with other studies, where protection of dopaminergic
somata against MPTP-induced cell death did not extend to the striatal
dopaminergic ﬁbres (Dehmer et al., 2000; Tieu et al., 2004; Liberatore
et al., 1999). This might also explain why DFU and/or JZL184 treatment
failed to attenuate any MPTP-induced behavioural changes. Although itis interesting to note that there was no signiﬁcant difference between
the MPTP group treated with JZL184 as well as the one treated with
both DFU and JZL184 and their corresponding control group, putting it
more in line with the ﬁndings of Fernandez-Suarez et al. (2014). Inter-
estingly enough, it was shown thatMPTP leads to an increase in CB2 ex-
pression in the SNpc but not the striatum (Price et al., 2009), thus the
approach of affecting 2-AG levels might have a more substantial beneﬁt
in the nigra due to the increased presence of CB2.
In summary, our results show that the endocannabinoid 2-AG is
neuroprotective in the MPTP mouse model. The beneﬁts can be
achieved both by exogenous addition of 2-AG and by speciﬁcally
inhibiting the enzyme MAGL, which controls the ligand's metabolism,
with the infusion of JZL184. Further studies using animals lacking CB1
or CB2 should verify if both CB1 and CB2 receptors are needed to ensure
that the full spectrum of 2-AG neuroprotective properties can be
achieved. Further work should focus on a more detailed delineation of
the mechanism by which 2-AG works, and possible ways to potentiate
its action.
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doi.org/10.1016/j.expneurol.2015.07.024.Acknowledgements
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